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Sumiar Prostate-specific antigen (PSA) was recently found in 30% of female breast tumours. In this study
we have examined if PSA circulates in the blood of breast cancer patients and if serum PSA has any clinical
application. We have compared serum PSA levels between women with and without breast cancer, between
women with PSA-positive and PSA-negative breast cancer and between women with breast cancer before and
after surgical removal of the tumour. We found that for women > 50 years, there is no difference in serum
PSA between normal or breast cancer patients. We also could not find any difference in presurgical or
post-surgical serum PSA between women who have PSA-positive or PSA-negative breast cancer. We found no
correlation between PSA concentrations in matched presurgical and post-surgical sera, between presurgical
sera and tumour cytosols and between post-surgical sera and tumour cytosols. High-performance liquid
chromatography has shown that PSA in normal male serum consists mostly of PSA bound to l,-
antichymotrypsin (molecular weight approximately 100 000), and PSA in breast tumours and presurgical and
post-surgical serum consists mostly of free PSA (molecular weight approximately 33 000). These data suggest
that female serum PSA is not associated with tumour PSA levels. We speculate that most of the circulating
PSA in women originates from the normal breast. It appears that serum PSA in women does not have
potential for breast cancer diagnosis or monitoring, but our previous data are consistent with the view that
tumour PSA concentration is a favourable prognostic indicator in women with breast cancer.
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Prostate-specific antigen (PSA) is a 33 kDa serine protease
found at high concentrations in seminal plasma and prostate
epithelial cells and at relatively low concentrations in male
serum (Oesterling, 1991: Armbruster, 1993). PSA production
is regulated by androgenic steroids, which bind to androgen
receptors and up-regulate transcription of the PSA gene
(Young et al., 1991). PSA was until recently thought to be
produced only by prostatic epithelial cells and is currently
used as a biochemical marker for diagnosis and monitoring
of prostate adenocarcinoma. We have reported that PSA
concentrations > 0.03 ng per mg of total protein could be
detected in 30% of cytosolic extracts from female breast
tumours (Yu et al., 1994). The PSA immunoreactive species
in female breast cancer has molecular weight identical to
PSA from seminal plasma (Diamandis et al., 1994). PSA
mRNA was identified by polymerase chain reaction in PSA
protein-positive breast tumours but not in PSA protein-
negative breast tumours (Monne et al., 1994). The PSA
cDNA from breast tumours was identical in sequence to PSA
cDNA from prostatic tissue (Monne et al., 1994). Preliminary
clinical studies have shown that PSA in breast cancer is
associated with the presence of the progesterone receptor (Yu
et al., 1994) and that patients with PSA-positive tumours
have a lower risk of relapse and death in comparison with
patients whose tumours are PSA negative (Yu et al., 1995a).
Thus, PSA is a new candidate favourable prognostic
indicator in female breast cancer.
A number of previous studies have shown that PSA is
undetectable in the serum of most women (Chan et al., 1987;
Rock et al., 1987; Vihko et al., 1990) and that fewer than 5%
of women have serum PSA concentrations > 0.05 iLg 1- (Yu
and Diamandis, 1995a). No study has as yet been published
examining whether serum PSA concentrations are higher in
women with breast cancer than in healthy controls or wheth-
er the PSA levels in the breast tumour affect the PSA concen-
tration in the serum. Currently, there is no established diag-
nostic value of PSA measurements in female serum. This
study was conducted in an attempt to answer the questions
raised above and further examine if serum PSA measure-
ments in female serum have any diagnostic, prognostic or
monitoring value. We have compared serum PSA levels
between women with and without breast cancer, between
women with PSA-positive and PSA-negative breast cancer
and between women with breast cancer before and after
surgical removal of tumour.
Materials and metods
Human subjects
Two hundred patients with primary breast cancer, operated
on at the Department of Gynecologic Oncology, University
of Turin, Italy, between January 1992 and May 1993, were
included in this study. These patients represent consecutive
cases for which sufficient tumour tissue remained after
routine pathological examination and steroid hormone recep-
tor analysis. The patients were aged between 29 and 93 with
a median age of 57. The clinical stages (Spiessl et al., 1989)
of these patients were 44% stage I, 48% stage II and 8%
stage III or IV. The tumour size ranged from 0.1 to 15 cm
with a median of 2 cm. Of the 200 patients, 185 had their
axillary lymph nodes examined at surgery; the median
number of nodes examined was 15. Of the 185 patients, 99
were found to have cancer metastasis to their axillary lymph
nodes. The major histological types of cancer in this group
were invasive ductal (56%) and invasive lobular (16.5%).
The rest included ductal in situ (2%), medullary (2%), papil-
lary (4.5%), tubular (6.5%), inflammatory (3.5%), tubulo-
lobular (4%), muciparous (2.5%) and others (2.5%).
Of the 200 patients. 198 had their presurgical serum col-
lected and stored at -20'C, 199 had their cancer tissue
specimens collected at surgery and stored at -70°C (snap-
frozen tumour tissue) and 119 had their post-surgical serum
taken 6 months after surgery and stored at -20'C.
Pre- and post-surgical sera from another 346 breast cancer
patients were also collected. These patients were aged
between 26 and 91 with a median age of 60. Clinical inform-
ation and tumour specimens were not available for these
patients.
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Received 3 March 1995: accepted 7 April 1995Sera provided by the Red Cross Blood Transfusion Service
in Toronto were collected from 674 female blood donors
between 17 and 69 years of age with a median age of 35.
These sera were taken from healthy women without clinically
diagnosed breast cancer. The blood donors were considered
the normal control group.
C}vtosolpreparation
Tumour tissue specimens were extracted as follows. Approx-
imately 0.2 g of tissue from each tumour was pulverised
manually with a hammer to a fine powder at - 80°C. The
cells were lysed for 30 min on ice with 1 ml of lysis buffer
(50 mmol l-1 Tnrs buffer. pH 8.0, containing 150 mmol 1-'
sodium chlonrde, 5mmoll-1 EDTA, lOg I` Nonidet NP-40
surfactant and 1 mmol l1 phenylmethysulphonyl fluoride).
The lysates were centrifuged at 15000g at 4°C for 30min
and the supernatants (cytosolic fractions) were assayed for
PSA and total protein.
High-performance liquid chromatography (HPLC)
In order to compare the molecular weight of PSA in female
serum, breast cancer cytosol and male serum. HPLC analysis
was performed with a Shimadzu system (Shimadzu. Kyoto,
Japan). using a mobile phase of 0.1 mol 1-' sodium sulphate
and 0.1 mol 1-l sodium dihydrogen phosphate, pH 6.80. The
column used was a Bio-Sil SEC-250. 600 mm x 75 mm
(BioRad Labs. Richmond. CA. USA) and was calibrated
with a molecular weight standard solution from BioRad. The
flow rate was 0.5 ml min-'. After injection of 50-300 jul of
each sample. fractions of 0.5 ml were collected and analysed
for PSA using the method outlined below.
MVeasurement ofPSA and totalprotein
PSA concentration in serum and in tumour cytosol was
measured in duplicate with a time-resolved immunofluoro-
metric PSA assay (Yu and Diamandis. 1993). which has a
biological detection limit of 0.01 jg 1-'. PSA concentration in
tumour cytosols was expressed as ng of PSA per mg of total
protein. The total protein concentration (mg ml-') in the
cytosols was measured in duplicate using a commercial kit
based on the bicinchoninic acid method (Pierce. Rockford,
IL. USA).
Statistical analysis
PSA concentrations in serum were categorised into three
groups as follows: PSA <0.010 ig 1-'. PSA between 0.010
and 0.029 jLg I` and PSA ) 0.030 jg I-'. Using the con-
tingency table and chi-square test (or Fisher's exact test when
necessary). we compared the differences in PSA concentra-
tion between breast cancer patients and normal women.
between presurgical and post-surgical serum and between
patients with PSA-positive and PSA-negative breast cancer.
PSA-positive breast cancer was defined as a cancer with a
PSA concentration ) 0.03 ng mg-' in the tumour cytosol.
The selection of this cut-off point was based on criteria
described elsewhere (Diamandis et al.. 1994).
Pearson correlation coefficients were calculated for PSA
concentrations between matched (i.e. from the same patient)
presurgical and post-surgical sera. matched presurgical sera
and tumour cytosols and matched post-surgical sera and
tumour cytosols. The McNemar test was also used for com-
parison of PSA status, categorised into positive and negative
groups with a cut-off level of 0.01 jIg ml-' for serum and
0.03 ng mg-' for tumour cytosols.
Results
The distribution of PSA concentrations in the serum of
healthy women, the serum of women with breast cancer
before or after surgery and in breast cancer cytosols is shown
Serum PSM in wmen with breaS cancer
M Gia etal 0
729
in Table I. The percentage of sera from presurgical breast
cancer patients with PSA ) 0.03 jig I' is higher than the
percentage of normal sera (110% vs 4%. P = 0.001). Similarly.
the percentage of sera from post-surgical breast cancer
patients with PSA > 0.03 jg I` is higher than the percentage
of normal sera (9% vs 4%, P = 0.045). No difference was
seen between presurgical and post-surgical sera (11% *s 900
P = 0.86). The percentage of breast tumour cytosols with
PSA ) 0.03 ng mg-' (26-33%) is higher than the percentage
of sera of either normal or breast cancer patients (P<0.001
for all comparisons and all age groups).
Similar statistical analysis was performed after all subjects
were classified into two age groups. i.e. < 50 years and > 50
years. In the younger age group, the percentage of sera with
PSA >0.03 ig 1-' was still higher in the presurgical breast
cancer group than in the healthy group (12% vs 4%.
P= 0.003). However, no difference was seen between sera
from healthy women and women with breast cancer. post
surgery (3% *s 4%. P = 0.52). In the older age group the
percentages of sera with PSA . 0.03 jig I' were similar in
the healthy. presurgical or post-surgical groups (9% vs 11%
vs 10%, P>0.8 in all cases) (Table I).
We have further compared the percentages of sera with
PSA > 0.03 jg I-' between the group of breast cancer
patients without any clinical information (n = 346) and heal-
thy women. No statistically significant difference was found
(P = 0.093 for ages < 50 years and P = 0.33 for ages ) 50
years).
The distribution of PSA concentrations in the serum of
presurgical or post-surgical breast cancer patients whose
tumours are either PSA positive or PSA negative is shown in
Table II. The percentage of presurgical sera with
PSA ) 0.03 jg I` was higher when the tumours were PSA
negative. but the difference was not statistically significant
(13% vs 7%. P = 0.053). Similarly. no difference was seen
Table I PSA concentration in the serum of healthv women. breast
cancer patients before and after surgery and in breast tumour
c-tosols
PSA (Lg 1` in serum or ng mg- in c!tosol)
Sample <0.010 0.010-0.029 ) 0.030 Total
1. Serum of healthy women'
All subjects 561 (83.2)b 86 (12.8) 27 (4.0) 674
<50years 478 (83.6) 76 (13.3) 18 (3.1) 572
>50years 83 (81.4) 10(9.8) 9 (8.8) 102
2. Serum of breast cancer patients before surgery
All subjects 154 (77.8) 22 (11.1) 22 (11.1) 198
< 50vears 44 (77.2) 6 (10.5) 7 (12.3) 57
>1 50 years 110 (78.0) 16 (11.4) 15 (10.6) 141
3. Serum of breast cancer patients post surgery
All subjects 95 (79.8) 13 (10.9) 11 (9.3) 119
<50 years 18 (78.3) 4 (17.4) 1 (4.3) 23
.S0years 77(80.2) 9(9.4) 10(10.4) 96
4. Tumour cytosolic extracts
All patients 40 (20.1) 103 (51.8) 56 (28.1) 199
<50 years 9 (15.8) 29 (50.9) 19 (33.3) 57
)50years 31 (21.8) 74 (52.1) 37 (26.1) 142
5. Serum of breast cancer patientsc
All patients 299 (86.4) 23 (6.7) 24 (6.9) 346
<50 years 67 (83.8) 7 (8.7) 6 (7.5) 80
) 50 years 232 (87.2) 16 (6.0) 18 (6.8) 266
aStatistical analysis - all subjects. two degrees offreedom: 2 = 14.6
P= 0.001. for 1 and 2: /=6.2. P= 0.045. for I and 3: 2= 0.29.
P = 0.86. for 2 and 3. Patients < 50 years. two degrees of freedom:
f = 11.4. P = 0.003. for I and 2: P = 0.52 with Fisher's exact test
)two-tail) for I and 3: P = 0.47 with Fisher's exact test for 2 and 3.
Patients >50years: ,=0.41. P=0.81. for 1 and 2: jf=0.15.
P = 0.93. for I and 3; jy = 0.25. P = 0.88. for 2 and 3. Other data are
presented in the text. bNumber ofpatients with percentage in brackets.
'For this group of breast cancer patients no clinical information was
available.SwX PSA hinwm wih brst c
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between the sera from post-surgical patients with PSA-
positive or PSA-negative tumours (P = 0.45, Table II).
We have also correlated the PSA concentrations between
presurgical and post-surgical sera (n = 118 pairs), between
presurgical sera and tumour cytosols (n = 197) and between
post-surgical sera and tumour cytosols (n = 119). The Pear-
son correlation coefficients were all below 0.02 and none was
statistically significant (P . 0.78 in all three cases.
We have also analysed the possible associations of PSA
levels between presurgical sera and tumour cytosols using
categorical data and the McNemar test. PSA cut-off levels
used were 0.01 jigl- for serum and 0.03 ngmg-1 for the
tumours. There were 109 serum/tumour pairs negative for
PSA, 33 pairs which were positive for PSA in the serum and
negative in the tumour, 44 pairs which were negative in the
serum and positive in the tumour and 11 pairs positive for
PSA in both the serum and tumour. The P-value was 0.21,
indicating no statistical significance.
From the statistical analysis we concluded that high levels
of PSA in the tumour were not correlated with high PSA
levels in the presurgical sera.
We have performed high-performance liquid chromato-
graphic separation of the serum PSA subfractions (Figure 1).
For this experiment we used a serum from a normal male, a
PSA-positive breast tumour cytosol, a serum from a female
with breast cancer collected before surgery and a serum from
a female with breast cancer collected post surgery. Normal
male serum contains both free PSA (PSA) and PSA bound to
a,-antichymotrypsin (ACT-PSA), the predominant form
being ACT-PSA. In breast tumours and female serum the
major fraction appears to be free PSA.
Dicesson
As PSA is found in 30% of breast cancer cytosols, it is
worthwhile examining if PSA is also present in the serum of
breast cancer patients and if the serum levels have any
clinical implication. We were able to study this question in
detail by simultaneously examining tumour PSA levels and
matched presurgical and post-surgical serum samples as well
as sera from normal women.
Comparisons of serum PSA levels between 674 normal
women, 198 women with breast cancer from Italy and 346
Table 11 PSA concentration in presurgical and post-surgical sera from patients with
either PSA-positive or PSA-negative breast cancer
PSA (igl-')
<0.01 0.01-0.029 > 0.030 P
Presurgical serum
PSA-positive cancer 44 (80%) 7 (13%) 4 (7%)
PSA-negativecancer 109 (77%) 15(11%) 18 (13%) 0.53a
Post-surgical serwn
PSA-positive cancer 32 (87%) 2 (5%) 3 (8%)
PSA-negative cancer 63 (77%) 11 (13%) 8 (10%) 0.45b
aChi-square test with two degrees of freedom. bFisher's exact test (two-tail).
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Figue 1 Separation of serum PSA by high-performance liquid chromatography and assay of the fractions by the time-resolved
immunofluorometric procedure. (a) Male serum. (b) Breast tumour cytosolic extract. (c) Presurgical female serum. (d) Post-surgical
female serum. The PSA-cl-antichymotrypsin complex (ACT-PSA) elutes at fraction 30 ± 1 (molecular weight approximately
100 000). Free PSA (PSA) elutes at fraction 39 ± 1 (molecular weight approximately 33 000). The major peak in male serum is
ACT-PSA. The major peak in female serum and breast tumour extracts is free PSA.
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women with breast cancer from Canada have shown slight
increases in PSA levels among women with breast cancer
(Table I). However, since elderly normal women tend to have
higher PSA levels in their serum than younger women (Yu
and Diamandis. 1995a) and younger breast cancer patients
tend to have more frequently PSA-positive breast cancer (Yu
et al., 1994). we have further analysed the data after stratify-
ing women according to age, i.e < 50 years and > 50 years.
PSA levels in sera from normal women and breast cancer
patients were not different in the older patient groups. In the
younger patient groups the PSA levels were slightly higher in
the presurgical sera, but not in the post-surgical sera. in
comparison with sera from normal women. Based on these
observations it seems unlikely that the PSA levels in the
serum of breast cancer patients are significantly different
from the PSA levels in the serum of normal women,
especially for women >50 years. in whom breast cancer is
more prevalent.
The PSA concentration in the tumour cytosols does not
seem to influence the PSA concentration in the serum of
breast cancer patients. This suggestion is based on the fol-
lowing data. First, we did not observe higher serum PSA
levels in PSA-positive cancers than in PSA-negative cancers
(Table II). Second, no correlation was found between PSA
levels in the presurgical sera and cancer cytosols. Third, no
association was found between positive tumour and positive
presurgical sera when the data were examined categorically
by the McNemar test. Fourth, by examining matched presur-
gical and post-surgical sera. the PSA status im the serum did
not change significantly when the cancer was removed.
In this study we did not find any association between
serum PSA and tumour cytosol PSA. However, our previous
study. which examined levels of PSA in amniotic fluid and
maternal serum at vanrous gestational ages, showed that the
two values change in parallel. following a very similar pat-
tern. Moreover, we have demonstrated that serum levels of
PSA are higher in pregnant women than in non-pregnant
women (Yu and Diamandis, 1995b). PSA was also found in
the milk of lactating women and in normal breast, especially
after stimulation by oral contraceptives. These two findings
suggest that PSA is produced not only by breast tumours,
but also by the normal breast cells (Yu and Diamandis,
1995c; Yu et al., 1995b).
There are several possibilities which may have obscured an
association between serum PSA and tumour cytosol PSA.
For example. patients who have PSA-positive cancer and
PSA-negative serum may have some PSA in the serum that is
not measurable by the method used. PSA levels in breast
tumours are much lower than PSA levels in the prostate.
Based on the ratio of PSA concentration in seminal plasma
and serum (approximately 106) we may expect that serum
PSA originating from the breast tumour is at a level below
0.01 lg -1 in most cases. In the prostate, PSA enters the
circulation through physical diffusion (Oesterling et al., 1988;
Oesterling. 1991). Factors that affect the transport of PSA
from the tissue to the blood may also be considered when
one examines the relationship between PSA levels in the
serum and tissue.
For those patients who had PSA-negative tumours and
PSA-positive serum, there are at least two possible reasons to
explain the phenomenon. First, it is conceivable that PSA is
produced by foci of cells scattered throughout the tumour
and that the examined tissue was negative owing to sampling
bias. Second, we found that PSA can be produced by the
normal breast tissue as well (Yu and Diamandis, 1995c: Yu
et al., 1995b). Consequently, the serum PSA circulating in
some women with or without cancer is probably released by
the breast epithelial cells under stimulation by endogenous or
exogenous steroid hormones. In the limited number of sam-
ples analysed, it appears that most of the PSA is present in
its free form in the female serum but is present as ACT-PSA
in the male serum (Figure 1). Free PSA also predominates in
the breast tumour.
In summary, we found that there is no substantial
difference between serum PSA levels from normal women
and from women with breast cancer. No association was
found between tumour PSA levels and serum PSA or
between presurgical and post-surgical serum PSA levels.
Based on these data we conclude that serum PSA levels are
not useful for breast cancer patient diagnosis or monitoring.
However, tumour levels of PSA appear to be valuable for
breast cancer patient prognosis, since patients with PSA-
positive tumours have much longer disease-free and overall
survival (Yu et al.. 1995a).
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